Are Vertex PharmaOption Buyers Banking On a Bid?

Vertex Pharmaceuticals Incorporated (VRTX) calls are hot amid hopes for a Gilead Sciences, Inc. (GILD) bid

Apr 21, 2015 at 2:14 PM
facebook twitter linkedin


Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is flirting with a 5.1% lead at $132.11, after analysts at Bernstein urged a buyout bid from fellow drugmaker Gilead Sciences, Inc. (NASDAQ:GILD). What's more, VRTX option traders are seemingly hoping the takeover chatter comes to fruition, with bullish bets crossing the tape at six times the average intraday rate.

VRTX has seen close to 3,000 calls change hands thus far, compared to fewer than 600 puts. Most popular is the out-of-the-money May 140 call, where buy-to-open action has transpired. By purchasing the call at a volume-weighted average price (VWAP) of $4.96, the buyers will make money if VRTX conquers $144.96 (strike plus VWAP) -- in uncharted territory -- by the close on Friday, May 15, when front-month options expire.

Today's appetite for long calls over puts marks a change of pace for VRTX. On the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX), the equity's 10-day put/call volume ratio of 1.46 stands higher than 89% of all other readings from the past year. In other words, option buyers have scooped up VRTX puts over calls at a faster-than-usual clip during the past two weeks.

On the charts, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has been a standout, touching a record high of $136.33 just over a month ago. What's more, the equity has been historically stellar in the second quarter, and is already up 11.7% so far in April.

 

If you are not making money with options, you aren’t buying options like this…

There is no options strategy that more perfectly approaches trading the fastest moving and most volatile stocks available in the marketplace than this one. In fact, there is no strategy that better utilizes put options for optimal returns and a real trading edge over other traders in the exact same market. New options traders fail out at an incredible rate without proper trade research, execution timing, and option picking. Capitalize on Schaeffer’s 100+ years of options trading excellence with the most coveted product launch in company history. Don't waste another second... join us right now before the next round of trades are released!

SCHAEFFER'S JULY STOCKS REPORT AD
 


 


 
Special Offers from Schaeffer's Trading Partners